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ABSTRACT Chronic obstructive pulmonary disease (COPD) patients are at increased risk of developing
nonsmall cell lung carcinoma, irrespective of their smoking history. Although the mechanisms behind this
observation are not clear, established drivers of carcinogenesis in COPD include oxidative stress and
sustained chronic inflammation. Mitochondria are critical in these two processes and recent evidence links
increased oxidative stress in COPD patients to mitochondrial damage. We therefore postulate that
mitochondrial damage in COPD patients leads to increased oxidative stress and chronic inflammation,
thereby increasing the risk of carcinogenesis.
The functional state of the mitochondrion is dependent on the balance between its biogenesis and
degradation (mitophagy). Dysfunctional mitochondria are a source of oxidative stress and inflammasome
activation. In COPD, there is impaired translocation of the ubiquitin-related degradation molecule Parkin
following activation of the Pink1 mitophagy pathway, resulting in excessive dysfunctional mitochondria.
We hypothesise that deranged pathways in mitochondrial biogenesis and mitophagy in COPD can account
for the increased risk in carcinogenesis. To test this hypothesis, animal models exposed to cigarette smoke
and developing emphysema and lung cancer should be developed. In the future, the use of mitochondria-
based antioxidants should be studied as an adjunct with the aim of reducing the risk of COPD-associated
cancer.
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Lung cancer is a common and deadly malignancy worldwide [1]. Nonsmall cell lung carcinoma (NSCLC),
which accounts for 87% of lung cancer, usually presents at a late stage with locally advanced or metastatic
disease in 80% of cases [2], which largely explains its dismal prognosis of 15% survival at 5 years
post-diagnosis [3]. The advent of molecular targeted therapies has led to an improved outcome in patients
with metastatic pulmonary adenocarcinoma that harbours an activated oncogene, such as epidermal
growth factor receptor (EGFR) [4, 5]. However, these patients constitute only a fraction of the total
number of lung cancer sufferers, and even in these patients long-term disease control is not achieved [6].
Novel detection and treatment strategies for lung cancer are therefore urgently required to improve this
dismal current prognosis of lung cancer. To achieve this, we need to understand how known risk factors
can trigger the mechanisms of lung carcinogenesis in its early stages.
The clinical links between COPD and lung cancer
Up to 85% of lung cancer is related to smoking. Yet, only 15% of smokers will develop lung cancer and
10–25% of lung cancer sufferers are never-smokers [7]. Of the lung cancer smokers, between 50% and
70% have pre-existing chronic obstructive pulmonary disease (COPD) prior to cancer diagnosis [8, 9] The
annual incidence of lung cancer arising from patients with COPD has been reported to be 0.8–1.7% [10, 11].
COPD per se is a risk factor for developing lung cancer, irrespective of the fact that smoking is a common
risk factor to both conditions. As early as 1986, an association between airflow obstruction and increased
incidence of lung cancer was noted [12]. This observation has since been confirmed in larger studies that
have carefully controlled for cigarette smoke consumption [8, 10, 13–16]. Smokers with airflow obstruction
have a five-fold increased risk of lung cancer compared with those with normal lung function [8]. A
reduction of 10% in the predicted forced expiratory volume in 1 s was associated with a nearly three-fold
greater lung cancer risk [16]. In a large cohort of >2500 COPD patients followed up to 90 months, 215
patients developed lung cancer (incidence density of 16.7 per 1000 person-years) [17]. In addition, stage 1
NSCLC patients, who undergo lung resection, are more likely to have tumour recurrence if they have
COPD [18].
As well as airflow obstruction, emphysema diagnosed by computed tomography (CT) is also an
independent risk factor for lung cancer [19, 20]. A meta-analysis also concluded that CT-diagnosed
emphysema was a negative prognostic factor for the overall survival of patients, independent of tumour
staging [21]. A recent study from the Multi-Ethnic Study of Atherosclerosis group showed that
emphysema on CT in the general population, irrespective of their smoking history, conferred a three-fold
increased risk of respiratory mortality caused by lung cancer [22]. This effect on outcome was also
dependent on the severity of emphysema in two additional studies [23, 24]. Lung cancers tend to arise
within areas of worse regional emphysema, as detected on CT [23, 24].
The above observations suggest that the risk of developing lung cancer in COPD patients is not solely
related to exposure to smoking, but that the development of airflow obstruction and emphysema are likely
to be additional drivers of lung carcinogenesis.
Molecular drivers of COPD-associated lung cancer in smokers and nonsmokers
Lung cancer patients who have smoked differ markedly in age of presentation, sex and geographical
incidence, compared with those who have not. The histological profile and molecular drivers of
carcinogenesis are also dependent on the patients’ smoking status, although there is some overlap between
the two groups of patients.
Nonsmokers
Nonsmokers who develop lung cancer tend to be younger, are more likely to be female and are more
common among Asians [25]. They also have a genetic predisposition to alterations in CYP1A1 and
GSTM1 genes (carcinogen metabolism), XRCC1 and ERCC2 genes (DNA repair genes) and the IL10 gene
(inflammatory response) [25, 26].
Adenocarcinomas form a much higher proportion of the histological classification of NSCLC in
nonsmokers (70%) than in current (40%) and former smokers (47%). Histologically, peripheral
adenocarcinomas in nonsmokers are preceded by atypical adenomatous hyperplasia and adenocarcinoma
in situ and are considered to originate from the terminal respiratory unit [27], which consists of
non-ciliated small bronchioles and pneumocytes [27].
Lung cancer in nonsmokers is more likely to be caused by a single driver oncogene mutation, unlike in
smokers [28]. Over half of primary lung adenocarcinomas harbour a known driver mutation, most
commonly in KRAS or EGFR [26]. In addition, EGFR mutations are more common in nonsmokers, being
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present in up to 40% of adenocarcinomas from an Asian nonsmoking population [29]. Other less
commonly altered genes in nonsmokers are ALK and ROS1, which account for 7–10% of NSCLCs. These
mutations are rare in squamous cell carcinoma (SQCC), which constitute only 18% of NSCLC in
nonsmokers [29].
Smokers
Lung cancer in smokers tends to be central in location with a predominance of SQCC [30]. It is thought
that the effect of carcinogens from tobacco smoke is greater in the proximal than the distal airways. When
both central and peripheral tumours are taken into account in smokers, the histological classification
consists of 48% of SQCC and 44% of adenocarcinoma [31].
KRAS mutations are more common in adenocarcinomas from smokers than those from nonsmokers [26,
32]. However, frequent and clinically relevant driver mutations in adenocarcinoma (in EGFR and KRAS)
are present in <5% of SQCC patients [29]. The most common genomic alterations in SQCC are the loss of
p53 and CDKN2A, but smoking-associated cancers harbour more widespread genetic changes. There are
currently no clinically approved target agents for SQCC being used for treatment. There is therefore an
urgent need to find novel ways of treating NSCLC associated with smoking, whether they are
adenocarcinomas or SQCCs.
COPD-associated NSCLC exhibited a low prevalence of EGFR and ALK driver mutations compared with
NSCLC patients who did not have COPD [33] and is not correlated with KRAS mutations [34]. However,
in these two studies [33, 34], SQCC and adenocarcinoma cases were not studied separately and were
grouped together as NSCLC patients. Future studies investigating the effect of COPD status on the
presence of driver mutations will need to separate these patients, according to the histology of their
cancers and their smoking status.
There is debate about whether the COPD status of lung cancer patients is a risk factor for a particular
histological subtype of NSCLC (adenocarcinoma versus SQCC). PAPI et al. [35] were the first to suggest
that COPD was an independent risk factor for SQCC, but not adenocarcinoma. This observation seemed
supported by a later study investigating the lung cancer subtypes associated with emphysema on CT [21].
However, a large cohort of 565 lung cancer cases from the Mayo clinic showed that emphysema is a risk
factor for both adenocarcinoma and SQCC [36].
Overall, COPD-associated NSCLC consists of a mixture of histological subtypes of NSCLC in both central
and peripheral locations. In a cohort of 230 patients with airflow limitation and emphysema, SHIN et al.
[37] found 37% of patients with central lung cancer, of which 76% were SQCC, 17% small cell carcinoma
and 5% adenocarcinomas. In the peripheral lung cancer, the histological subtype of NSCLC was
dependent on whether the tumour arose within an area of emphysema. SQCC was more frequently found
in emphysema areas than areas without emphysema, while the reverse was true for adenocarcinoma [37].
SQCCs are derived from bronchial epithelial cells with the well-established pathogenic sequence of
squamous metaplasia, dyplasia and carcinoma in situ in the central airways [30]. The SQCC may also
undergo the same pathological sequence in the smaller airways, but peripheral SQCCs are less common as
it is thought that the magnitude of the toxic effects of smoke are stronger in the central airways.
There is more debate on the cells of origin of adenocarcinomas. Immunohistochemical studies of human
lung cancer suggest that they derive from the terminal respiratory unit [27, 30]. Animal models of lung
adenocarcinoma also suggest that they tend to arise mostly from the terminal respiratory unit, in
particular the type 2 alveolar cells, but may also arise from a more proximal bronchioalveolar stem cells
niche [38].
Despite the low incidence of the aforementioned oncogene driver mutations, there is some evidence that
COPD-associated NSCLC may be driven by specific genetic mutations. In a limited direct comparison of
SQCC from patients with or without COPD, BOELENS et al. [39] showed that >370 genes are differentially
expressed, with 34 genes located on chromosome 5q and 44 genes related to mitochondrial function.
Aberrant DNA methylation of promoter sequences is a recognised factor in the pathogenesis of human
cancer. The differentially methylated and expressed genes in COPD-associated NSCLC versus
non-COPD-associated NSCLC are mainly involved in the immune response, in particular the innate
defence response, dendritic cell and lymphocyte trafficking [40], which is associated with a reduced
infiltration of CD3- and CD4-positive T-cells in the tumour microenvironment. The methylation of
tumour suppressor genes and apoptosis-related genes, such as mitochondrial transcription factor A, in
COPD-associated NSCLC has also been demonstrated [41, 42]. A recent study by XIAO et al. [43] showed
that lung adenocarcinoma patients with COPD have a higher prevalence of LDL receptor protein 1B
mutations than those without COPD.
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Oxidative stress and inflammation as the link between COPD and carcinogenesis
Multiple mechanisms, such as oxidative stress, chronic inflammation and genetic factors, have been
proposed to account for the link between COPD and lung cancer and have been reviewed elsewhere [44–
46]. Of those, oxidative stress and sustained chronic inflammation are well-established drivers of
carcinogenesis [47, 48]. Mitochondrial dysfunction is central to these two drivers of carcinogenesis in
COPD patients.
Smoking is a source of toxic chemicals and provides excessive exposure of the airways to reactive oxygen
species (ROS). However, COPD patients have an increase in oxidative stress compared with non-COPD
smokers. The airways of patients with COPD demonstrate an increase in mitochondrial ROS compared
with healthy smokers and nonsmokers [49], an effect at least partly due to mitochondrial damage.
Pathways involved in oxidant/antioxidant responses, such as superoxide dismutase, were among the most
differentially expressed gene pathways in the airways of COPD patients [50]. COPD patients also have an
impairment of antioxidant defences, such as NRF2 (nuclear factor erythroid 2-related factor 2) [51].
Excess ROS cause direct damage to genomic DNA, proteins and lipids [52]. DNA damage leads to point
mutations, strand breaks and cross-linking that may result in somatic mutations, which accumulate with
age and increases the predisposition to cancer. As expected, oxidative DNA damage is prominent in
COPD lungs [53, 54]. The expression of DNA damage/repair proteins also increases significantly with
worsening severity of the pre-neoplastic changes in the lung [55], further strengthening the hypothesis that
oxidative DNA damage is important in lung carcinogenesis. Since NSCLC originates from bronchial
epithelial cells or the terminal respiratory unit, it was thought that COPD-related molecular differences in
the epithelium would be magnified in NSCLC because of clonal expansion [56]. Indeed, oxidative
stress-related proteins, such as catalase and thioredoxin, in bronchoalveolar lavage fluid are differentially
expressed in both COPD and COPD-associated NSCLC compared with nonsmokers [57].
The effect of increased oxidative stress on carcinogenesis may also be mediated by the induction of cellular
senescence. Emphysematous lungs show evidence of cellular senescence and accelerated ageing with
shortened telomeres and decreased anti-ageing molecules [58]. As well as increased oxidative stress, cell
senescence is also known to be induced by mitochondrial dysfunction [59–62]. In addition to showing
irreversible growth arrest, senescent cells show a senescence-associated secretory phenotype, containing
factors with pro-tumorigenic properties [63, 64]. Inflammation is another critical driver for both COPD
and lung cancer. Macrophages and neutrophils infiltrate the lungs of all smokers. However, patients with
COPD develop more pronounced inflammation than smokers without COPD [54]. This inflammatory
infiltrate correlates positively with disease severity. This is further compounded by the impaired immune
response in COPD patients [65]. For example, programmed cell death protein (PD)-1 induces a loss of
cytotoxic function in T-cells and is upregulated in T-cells derived from patients with COPD [66].
Up to 20% of cancers are related to chronic inflammation caused by infection, irritants or autoimmunity
[67]. Large epidemiological studies have provided indirect evidence that chronic inflammation is associated
with lung cancer. In a cohort of >7000 patients without known malignancy followed for ∼10 years, the
likelihood of developing cancer was shown to be increased if C-reactive protein was >3 mg·dL−1 [68]. A
retrospective study of >10000 patients with COPD found that the risk of lung cancer was decreased
among patients taking inhaled corticosteroids at a dose of >1200 µg·day−1 compared with patients not
taking inhaled corticosteroids or taking lower doses [69]. Therefore, persistent inflammation is associated
with an increased risk of malignancy. This may be partially related to the activation of hypoxia-inducible
factor (HIF)-1α via hypoxia-controlled mechanisms in inflammation or the release of the inflammasome
via the mitochondrion, as will be discussed later in this review.
Although there is increased inflammation at the initiation stage of COPD-associated carcinoma, there is as
yet no known evidence whether there is increased inflammation with established COPD-associated cancer.
Further studies are awaited to determine whether COPD-associated NSCLCs have an inflammatory
stroma.
Mitochondrial dysfunction in lung cancer
Under physiological conditions, the mitochondrion is the main source of ROS, as a by-product of ATP
production from the oxidative phosphorylation system [70]. The mitochondrion is also the hub for
sensing inflammatory damage signals and is the site of the initiation of the inflammatory response. In
particular, mitochondria-derived proteins, such as mitochondrial antiviral signalling protein (MAVS),
initiate the NLRP3 inflammasome [71]. Inflammasomes are multimolecular complexes composed of a
sensor protein, an adaptor protein ASC and caspase-1. Conformational changes of this multimolecular
complex lead to the activation of caspase-1 and hence the induction of the pro-inflammatory cytokines,
such as interleukin (IL)-1β and IL-18 [72]. Currently, the identified inflammasome sensor proteins include
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the nucleotide-binding domain and leucine-rich repeat containing proteins (NLR), such as NLRP1, -3, -4
and -6 and NAIP5, as well as the DNA-sensing complex of the absent in melanoma 2 (AIM2) protein [73].
Deranged mitochondrial function in cancer was suspected as far back as 1956, when WARBURG [74]
discovered that cancer cells preferentially produce ATP by glycolysis, rather than by oxidative
phosphorylation as in normal cells, even in the presence of oxygen. This metabolic adaptation and
enhanced glucose uptake provides cancer cells with glucose metabolites, raw materials in the biosynthesis
of nucleic acids, amino acids and lipids in these rapidly dividing cell populations. These observations led
WARBURG [74] to postulate that mitochondrial respiration defects are the basis for carcinogenesis. Although
only a handful of cancers are now known to result from mutations in the metabolic enzymes within the
mitochondrion, somatic mutations of the mitochondrial genome are established factors in carcinogenesis [75].
However, there remains a paucity of studies detailing the mitochondrial abnormalities present in lung
cancer, when compared with other cancer types. Mitochondrial mutations have been reported in human
lung cancer, with some evidence that they are linked to the survival of the patients [76–80]. Damage to
lung mitochondrial DNA and related dysfunction has been linked with cigarette smoking [81–83].
Furthermore, this has been associated with the accumulation of mitochondrial DNA adducts resulting
from tobacco-related carcinogen metabolism over time, as a result of insufficient repair processes in rats
[84, 85]. Certainly, DNA adducts formed as a result of tobacco-specific nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism induced both nuclear and mitochondrial DNA
damage in exposed Caenorhabditis elegans, which was associated with reduced ATP production and oxygen
consumption [86]. At present, investigations in the context of mouse models of human lung cancer are
limited, but may provide a critical understanding of the underlying mechanisms of lung tumorigenesis.
It is postulated that mitochondrial dysfunction is involved in the initiation of both centrally and
peripherally located COPD-associated NSCLC. Impaired mitochondrial function in COPD contributes to
the production of excess ROS from cigarette smoke exposure within both central and peripheral airways,
as well as the terminal respiratory unit. However, there is a different progenitor cell population lining the
airways at different anatomical sites, leading to different histological subtypes of cancer (SQCC centrally
and a mixture adenocarcinoma and SQCC peripherally).
Altered mitochondrial dynamics in COPD and NSCLC
Cigarette smoke extract induces alterations in mitochondrial structure and function and leads to increased
expression of the mitochondrial fusion protein, Mfn-2, in alveolar epithelial cells [87]. However, there are
as yet no studies suggesting that alterations in mitochondrial fusion or fission are involved in the
pathogenesis of COPD. There is conflicting evidence about the role of these processes in NSCLC. Evidence
of mitochondrial fission in human lung cancer cell lines and adenocarcinoma has been reported, with an
increase in dynamin-related protein (DRP)-1 and decrease in Mfn-2 compared with background lung
tissue [88]. When this imbalance was corrected by increasing Mfn-2 expression and decreasing DRP-1 in
cell lines, there was a reduction of cell proliferation and an increase in apoptosis [88]. However, LOU et al.
[89] demonstrated that, in human lung adenocarcinoma, the expression of Mfn-2 was higher than in
adjacent background lung tissue.
Mitochondrial function is also intimately linked with oxygen homeostasis. Hypoxia, a defining feature of
COPD and lung cancer, elicits a number of adaptive responses via HIF-1α. The latter is expressed in the
large airways of patients with COPD, but not of smokers without COPD or of nonsmokers [90]. HIF-1α is
also overexpressed in 32–56% of NSCLC and is associated with worse prognosis [91, 92].
HIF-1α promotes glycolytic energy production by inducing genes that encode glucose transporters and
glycolytic enzymes and reduces oxidative phosphorylation within mitochondria [93]. This is the metabolic
phenotype described by WARBURG [74] in cancer cells. COPD patients also produce glucose at a faster rate
than healthy control subjects, with a higher glucose clearance [93]. HIF-1α may therefore provide the link
between hypoxia and mitochondria-based metabolic changes in both COPD and lung cancer.
Mitophagy in COPD and lung cancer
Mitophagy is initiated by membrane depolarisation or hypoxia, and is triggered by three main molecular
pathways: NIP3-like protein X (NIX)/BNIP3L, Pink1/Parkin and Fun14 domain containing 1 (FUNDC1)
[94–98]. BNIP3L and NIX initiate mitophagy through interactions with LC3 (microtubule associated
protein 1 light chain 3 alpha)-related molecules [99, 100], thereby linking the mitochondria directly to the
autophagosome for degradation. Pink1 is a serine/threonine kinase that phosphorylates the fusion protein
Mfn-2 [101, 102], which acts as a receptor for the E3 ubiquitin ligase Parkin [90]. Hypoxia promotes
mitophagy through dephosphorylation of the FUNDC1 protein, thereby facilitating its interaction with
LC3 [98].
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Depending on the cellular context, mitophagy has a positive role in controlling oxidative stress and
inflammation. Damaged mitochondria are prone to uncoupling and therefore lead to the release of further
ROS [103]. The activation of mitophagy therefore leads to the removal of damaged mitochondria and
reduces the release of ROS. Impaired mitophagy reduces clearance of damaged mitochondria, resulting in
increased ROS production and mitochondrial DNA accumulation in the cytoplasm. The subsequent
release of mitochondrial ROS leads to inflammation, particularly the enhanced expression of IL-1β and
IL-18 [104–106]. Mitophagy is therefore also a negative regulator of inflammasome activation [106, 107].
Therefore, mitophagy can be considered as having a tumour suppressive function by limiting the
production of excessive ROS [108] and by inhibiting inflammasome activation.
There is dysregulation of the Pink1/Parkin mitophagy pathway in the pathogenesis of COPD. MIZUMURA
et al. [109] showed there was stabilisation of Pink1 in cultured pulmonary epithelial cells exposed to
cigarette smoke. Somewhat unexpectedly therefore, a later study showed that there was decreased
expression of Parkin in COPD lungs [110]. One potential explanation is the observation that cigarette
smoke impairs the translocation of Parkin to damaged mitochondria and leads to the accumulation of
damaged mitochondria in lung fibroblasts and small airway epithelial cells [111]. Therefore, in COPD,
there is activation of Pink1, but impaired translocation of Parkin to the mitochondria. The decrease in
Parkin within COPD lungs was associated with increased ROS and senescence of the bronchial epithelial
cells [110].
Dysregulation of the Pink1/Parkin pathway has also been demonstrated in lung cancer. Diffuse
cytoplasmic expression of Pink1 was observed in lung SQCC, which contrasted with the granular
cytoplasmic pattern found in normal lung tissue [112]. The lack of a granular cytoplasmic pattern,
consistent with mitochondrial expression, suggests that aberrant expression of Pink1 may be associated
with lung carcinogenesis [112]. Human lung adenocarcinomas also express different Parkin isoforms that
may be linked to regulation of apoptosis, as well as mitophagy and mitochondrial fusion [113].
We therefore speculate that the dysfunctional Pink1/Parkin mitophagy pathway in COPD leads to an
excess of degenerate mitochondria and subsequent enhanced ROS release (figure 1). This would contribute
to oxidative DNA damage and increased chronic inflammation, leading to an increased likelihood for
carcinogenesis. Whether the other pathways of mitophagy, activated by BNIP3 or FUNDC1, are affected in
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FIGURE 1 The mechanisms by which mitochondrial dysfunction in chronic obstructive pulmonary disease
(COPD) lead to increased oxidative stress and inflammation, drivers of carcinogenesis. In COPD, there is an
increase in mitochondrial damage as a result of the release of mitochondrial antiviral signalling protein
(MAVS), reactive oxygen species (ROS) and mitochondrial DNA (mtDNA). Damaged mitochondria should
undergo physiological degradation, mitophagy. However, in COPD, the Pink1/Parkin mitophagy pathway is
disrupted and therefore mitophagy is impaired. The persisting damaged mitochondria are a source of
oxidants and can induce the NLRP3 inflammasome pathway. IL: interleukin; DAMPs: damage-associated
molecular patterns.
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Inflammasomes in COPD and lung cancer
In COPD, there is upregulation of the ATP-NLRP3 inflammasome pathway [114], with the release of the
downstream molecules, IL-1β and IL-18 [115, 116]. This is partially dependent on cigarette smoke
activation of a critical adaptor molecule of the NLRP3 pathway, MAVS [117]. Inhibition of MAVS and
NLRP3 inflammasome pathway could therefore reduce the chronic inflammation associated with COPD.
Components of the inflammasome pathway are also overexpressed in lung cancer, with AIM2 and NLRP3
as the major scaffolding proteins [118]. AIM2 is overexpressed in all subtypes of NSCLC while NLRP3 is
upregulated in adenocarcinoma, with expression limited to the malignant epithelial cells [118]. The role of
the inflammasome activation in the pathogenesis of lung cancer remains uncertain. However, activation of
the NLRP3 inflammasome increases the proliferation and migration of lung cancer cell lines [119]. It has
also been suggested that inflammasome activation could contribute to the immune response of lung cancer
[118], but there is no experimental evidence to support this hypothesis currently. Further studies should
investigate whether the targeting of the inflammasome activation in established lung cancers would alter
the associated immune response and hence improve outcome.
Targeting mitochondria to reduce COPD-associated carcinogenesis
In other oxidative stress-related pathologies, mitochondria-targeted antioxidants have been used in clinical
trials [120]. Further studies of the role of mitochondrial dysfunction in COPD-associated NSCLC hold the
promise that mitochondria-based drugs can be used as an adjunct for cancer treatment or as a
prophylactic drug in reducing lung cancer incidence in patients with COPD. For example, functional
studies, using mitochondria-targeted antioxidants, are required to determine the feasibility of reducing the
incidence of lung cancer in COPD by reducing oxidative stress. This will require the development of
animal models which combine both emphysema and lung cancer (as discussed in the next section).
The best characterised mitochondria-targeted antioxidant to date is MitoQ, which is made of lipophilic
triphenylphosphonium cations, attached to coenzyme Q10, allowing it to easily pass through phospholipid
bilayers. MitoQ is driven by the large mitochondrial membrane potential and accumulates at a high
concentration in the mitochondria [120]. It is then reduced by the respiratory chain to its active ubiquinol
form, which prevents lipid peroxidation and mitochondrial damage. In clinical trials, MitoQ has been used
safely in patients with Alzheimer’s disease and reduced liver damage following hepatitis C infection [120].
A different class of mitochondria-targeted antioxidants are small cell-permeable peptides, called SS (Szeto–
Schiller) peptides [121], that contain an amino acid sequence that allows them to freely penetrate cells in
an energy-independent nonsaturable manner and partition in the inner mitochondrial membrane. They
scavenge ROS and inhibit low-density lipid peroxidation.
As well as the treatment of lung cancer, mitochondrial dysfunction may be further explored to reduce the
incidence of lung cancer. Currently, it is not possible to screen the entire at-risk population for lung
cancer because of the large numbers of individuals concerned. Screening a more limited population may
be feasible. Therefore, further criteria are required to restrict screening to patients who are at even greater
risk than the average smoker. Patients with COPD define a population that is at a particularly high risk for
lung cancer and may represent a target for screening. The expression of some mitochondria-related
proteins is related to the outcome of lung cancer [122, 123], thereby raising the possibility that they can be
used as biomarkers for lung cancer.
Mouse models of COPD-associated lung cancer
Murine models that accurately mimic the transformation of COPD to NSCLC are urgently required.
Murine models of lung cancer are widely available [124], but a large proportion comprises transgenic mice
with deletions of tumour-suppressor genes or with lung-specific overexpression of key oncogenes [125,
126] or patient-derived xenograft models [127]. These models are excellent for investigating specific
signalling pathway interactions involved in tumorigenesis, but they do not model the effects of cigarette
smoking and COPD on lung carcinogenesis.
In order to incorporate the risk factors for lung cancer, and best represent human disease, carcinogen
models need to be employed in conjunction with cigarette smoke exposure. Importantly, susceptibility to
developing lung cancer either spontaneously or as a result of chemical induction/smoke exposure varies
greatly between wild-type mouse strains much in the way it does in humans. The C57BL/6 mouse strain is
regarded as resistant, whereas BALB/c mice exhibit an intermediate susceptibility [128, 129]. The strains
displaying the highest level of susceptibility are A/J and SWR mice, and these strains are most commonly
used to model lung tumours in vivo. Although these models are useful, they are very long and expensive
to run, meaning that critical information that may lead to improvements for lung cancer patients is
generated slowly.
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Thus, the development of short-term models that develop the hallmarks of cigarette smoke-induced
COPD and lung cancer is vitally important to gain a better understanding of the mechanisms of lung
cancer in a timely manner. We have recently refined this model of combined carcinogen and cigarette
smoke exposure down to 17 weeks based on our more rapid model of induction of COPD (unpublished data).
Conclusion
Novel strategies in the prevention and treatment of lung cancer are required. We need to continue
exploring new pathways by which lung carcinogenesis is initiated to provide further targeted treatment
regimes for specific subsets of lung cancer, one of which may be mitochondrial dysfunction-driven
COPD-associated NSCLC.
Established drivers of carcinogenesis in COPD include oxidative stress and sustained chronic
inflammation. Dysfunctional mitochondria are a source of oxidants and mitochondria-related proteins
control the activation of the NLRP3 inflammasome. The increased oxidative stress in COPD patients has
been linked to mitochondrial dysfunction, which is partly characterised by the impaired translocation of
Parkin following activation of the Pink1 mitophagy pathway. Further mitochondrial pathways are likely to
be altered in COPD and candidates for further investigation include mitophagy pathways induced by
BNIP3 and FUNDC1, and mitochondrial biogenesis pathways.
Although mitochondrial dysfunction seems to be a common feature in COPD patients, the specific
dysregulated mitochondrial pathways leading to carcinogenesis remain to be identified. Therefore, future
studies should attempt to define the mitochondria-related pathways which contribute to increased
oxidative stress and chronic inflammation in COPD and lung cancer and delineate those COPD patients
who will go on to develop cancer. Selective blockade of these pathways may provide novel avenues for
therapeutic intervention and the use of mitochondria-based antioxidants should be studied as an adjunct
in reducing the risk of COPD-associated cancer in animal models. Future clinical trials may then consider
the efficacy of mitochondria-targeted antioxidants as a prophylactic agent in reducing the incidence of
cancer in those at high risk.
Understanding the mitochondrial dysfunctions in COPD and potentially lung cancer may contribute to
the generation of specific biomarkers that would fine-tune the screening strategy. The development of
these biomarkers may help to identify COPD patients who will go on to develop lung cancer. The
possibility of treating established lung cancers with mitochondria-targeted agents as an adjunct will also
have to be considered.
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